Mustang Bio Inc (MBIO) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Mustang Bio Announces Closing of $4 Million Public Offering

WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Mustang Bio Announces Pricing of $4 Million Public Offering

WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR...

Form 8-K - Current report

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and...

Form 8-K - Current report

Form 8-K - Current report

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...